PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-20.40%
Negative net income growth while TRVN stands at 42.62%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
5.37%
Less D&A growth vs. TRVN's 19.72%, reducing the hit to reported earnings. David Dodd would confirm that core assets remain sufficient.
42.67%
Some yoy growth while TRVN is negative at -28.54%. John Neff would see competitor possibly managing deferrals more aggressively for short-term advantage.
-15.52%
Negative yoy SBC while TRVN is 9.15%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
2.45%
Slight usage while TRVN is negative at -273.32%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-64.66%
Both negative yoy AP, with TRVN at -238.72%. Martin Whitman would find an overall trend toward paying down supplier credit in the niche.
389.89%
Some yoy usage while TRVN is negative at -49.43%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
-15.52%
Negative yoy while TRVN is 111.13%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-26.74%
Both yoy CFO lines are negative, with TRVN at -6.37%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
51.76%
CapEx growth well above TRVN's 69.16%. Michael Burry would suspect heavier cash outlays that risk short-term free cash flow vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative yoy purchasing while TRVN stands at 36.46%. Joel Greenblatt sees a near-term liquidity advantage unless competitor’s new investments produce outsized returns.
No Data
No Data available this quarter, please select a different quarter.
169.66%
We have some outflow growth while TRVN is negative at -11.98%. John Neff sees competitor possibly pulling back more aggressively from minor expansions or intangible invests.
253.33%
We have mild expansions while TRVN is negative at -9.08%. John Neff sees competitor possibly divesting or pausing expansions more aggressively.
100.00%
We repay more while TRVN is negative at -100.00%. John Neff notes advantage in lowering leverage if competitor is ramping up debt or repaying less.
-79.28%
Both yoy lines negative, with TRVN at -66.31%. Martin Whitman suspects an environment or preference for internal financing over new equity in the niche.
No Data
No Data available this quarter, please select a different quarter.